1. Home
  2. CRDL vs HIT Comparison

CRDL vs HIT Comparison

Compare CRDL & HIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • HIT
  • Stock Information
  • Founded
  • CRDL 2017
  • HIT 1964
  • Country
  • CRDL Canada
  • HIT United States
  • Employees
  • CRDL N/A
  • HIT N/A
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • HIT Specialty Insurers
  • Sector
  • CRDL Health Care
  • HIT Finance
  • Exchange
  • CRDL Nasdaq
  • HIT Nasdaq
  • Market Cap
  • CRDL 126.5M
  • HIT 122.9M
  • IPO Year
  • CRDL N/A
  • HIT 2024
  • Fundamental
  • Price
  • CRDL $1.31
  • HIT $3.52
  • Analyst Decision
  • CRDL Strong Buy
  • HIT Strong Buy
  • Analyst Count
  • CRDL 2
  • HIT 1
  • Target Price
  • CRDL $9.00
  • HIT $2.50
  • AVG Volume (30 Days)
  • CRDL 1.2M
  • HIT 2.2M
  • Earning Date
  • CRDL 08-26-2025
  • HIT 07-21-2025
  • Dividend Yield
  • CRDL N/A
  • HIT N/A
  • EPS Growth
  • CRDL N/A
  • HIT N/A
  • EPS
  • CRDL N/A
  • HIT 0.02
  • Revenue
  • CRDL N/A
  • HIT $26,692,318.00
  • Revenue This Year
  • CRDL N/A
  • HIT $70.02
  • Revenue Next Year
  • CRDL N/A
  • HIT $63.39
  • P/E Ratio
  • CRDL N/A
  • HIT $170.93
  • Revenue Growth
  • CRDL N/A
  • HIT 29.68
  • 52 Week Low
  • CRDL $0.77
  • HIT $0.51
  • 52 Week High
  • CRDL $2.63
  • HIT $7.59
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 51.92
  • HIT N/A
  • Support Level
  • CRDL $0.94
  • HIT N/A
  • Resistance Level
  • CRDL $1.55
  • HIT N/A
  • Average True Range (ATR)
  • CRDL 0.13
  • HIT 0.00
  • MACD
  • CRDL -0.00
  • HIT 0.00
  • Stochastic Oscillator
  • CRDL 59.74
  • HIT 0.00

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About HIT Health In Tech Inc. Class A Common Stock

Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.

Share on Social Networks: